MEDICINA
DEPARTAMENTO
Samsung Medical Center
Seúl, Corea del SurPublicaciones en colaboración con investigadores/as de Samsung Medical Center (1)
2023
-
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041